| Literature DB >> 19743561 |
Abstract
Ten years ago the National Institute for Health and Clinical Excellence (NICE) was set up to recommend to the National Health Services in England and Wales which treatments and procedures it should and should not pay for and to publish treatment guidelines. As the United States moves to engage in more study of the comparative effectiveness--and possibly the cost-effectiveness--of treatments, Sir Michael Rawlins, chairman of NICE since its inception, reflects on the lessons. A possible surprise: on balance, NICE has added to costs.Mesh:
Year: 2009 PMID: 19743561 DOI: 10.1377/hlthaff.28.5.1360
Source DB: PubMed Journal: Health Aff (Millwood) ISSN: 0278-2715 Impact factor: 6.301